Share on StockTwits

Gilead Sciences (NASDAQ:GILD) CFO Robin L. Washington sold 33,556 shares of the company’s stock on the open market in a transaction dated Thursday, August 14th. The shares were sold at an average price of $95.56, for a total value of $3,206,611.36. Following the completion of the sale, the chief financial officer now directly owns 49,832 shares in the company, valued at approximately $4,761,946. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Gilead Sciences (NASDAQ:GILD) traded up 1.24% during mid-day trading on Monday, hitting $100.72. 14,749,466 shares of the company’s stock traded hands. Gilead Sciences has a 1-year low of $56.75 and a 1-year high of $99.49. The stock has a 50-day moving average of $90.1 and a 200-day moving average of $81.24. The company has a market cap of $152.3 billion and a price-to-earnings ratio of 22.54. Gilead Sciences also was the recipient of some unusual options trading on Friday. Stock traders acquired 95,735 call options on the stock. This is an increase of approximately 217% compared to the average volume of 30,213 call options.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 23rd. The company reported $2.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.00 EPS for the current fiscal year.

GILD has been the subject of a number of recent research reports. Analysts at Cowen and Company raised their price target on shares of Gilead Sciences from $95.00 to $105.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Gilead Sciences in a research note on Friday. They set an “outperform” rating on the stock. Finally, analysts at FBR Capital Markets initiated coverage on shares of Gilead Sciences in a research note on Thursday. They set an “outperform” rating and a $125.00 price target on the stock. One research analyst has rated the stock with a hold rating and twenty-one have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $105.05.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.